{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"criteria of the International Myeloma Working Group","groups":[{"description":"The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT.\n\nIpilimumab: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.","id":"OG000","title":"Ipilimumab After Stem Cell Transplantation"}],"populationDescription":"Data were not collected","reportingStatus":"POSTED","timeFrame":"2 years","title":"Phase II: Progression Free Survival (PFS)","type":"PRIMARY"}